



Kent Academic Repository

Alam, Farhana, Blair, Jessica M A and Hall, Rebecca A. (2022) *Transcriptional profiling of Pseudomonas aeruginosa mature single and dual species biofilms in response to meropenem*. *Microbiology* . ISSN 1350-0872. (In press)

Downloaded from

<https://kar.kent.ac.uk/97904/> The University of Kent's Academic Repository KAR

The version of record is available from

This document version

Author's Accepted Manuscript

DOI for this version

Licence for this version

UNSPECIFIED

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal* , Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries

If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

1 **Transcriptional profiling of *Pseudomonas aeruginosa* mature single and dual species**
2 **biofilms in response to meropenem**

3
4 Farhana Alam¹, Jessica M. A. Blair², Rebecca A Hall^{3#}
5

6 ¹Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, B15
7 2TT

8 ²Institute of Microbiology and Infection, College of Medical and Dental Sciences, University
9 of Birmingham, B15 2TT

10 ³Kent Fungal Group, Division of Natural Sciences, School of Biosciences, University of Kent
11 CT2 7NJ

12
13 # corresponding author r.a.hall@kent.ac.uk
14
15

16 **Key words:** *Candida albicans*, *Pseudomonas aeruginosa*, meropenem, transcriptional
17 profiling, dual species biofilms
18

19
20 **Repositories:** Sequencing reads and gene hit count tables are available at the Gene
21 Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>), under accession
22 number GSE167137.

23 **Abstract**

24 *Pseudomonas aeruginosa* is a Gram-negative opportunistic pathogen frequently isolated from
25 chronic infections of the Cystic Fibrosis lung and burn wounds, and is a major cause of
26 antimicrobial resistant nosocomial infections. *P. aeruginosa* is frequently co-isolated with the
27 opportunistic fungal pathogen *C. albicans*, with the presence of *C. albicans* in dual species
28 biofilms promoting tolerance to meropenem. Here, transcription profiling of mature *P.*
29 *aeruginosa* single or dual species biofilms was carried out to understand the molecular
30 mechanism(s) by which *C. albicans* enhances meropenem tolerance. *C. albicans* appeared
31 to have a mild impact on the transcriptome of *P. aeruginosa* mature biofilms, with most
32 differentially regulated genes being involved in interkingdom interactions (i.e. quorum sensing,
33 and phenazine biosynthesis). The addition of meropenem to mature single or dual species
34 biofilms resulted in a significant bacterial transcriptional response, including the induction of
35 the beta-lactamase, *ampC*, genes involved in biofilm formation. *P. aeruginosa*, elicited a
36 similar transcriptional response to meropenem in the presence of *C. albicans*, but *C. albicans*
37 promoted the expression of additional efflux pumps, which could play roles in increasing the
38 tolerance of *P. aeruginosa* to meropenem.

39

40

41

42

43 Introduction

44 *Pseudomonas aeruginosa* is a Gram-negative bacterial pathogen associated with chronic
45 infections in the Cystic Fibrosis (CF) lung (Lyczak *et al.* 2002), burn wounds (Ramakrishnan
46 *et al.* 2016) and is a major contributor to nosocomial infections (Chatterjee *et al.* 2016). The
47 ability of the bacterium to form biofilms is critical to the pathogenicity of *P. aeruginosa*, with
48 biofilms being the predominant mode of growth in both the CF lung and wounds (Bjarnsholt *et*
49 *al.* 2009, Fazli *et al.* 2009). Biofilms are of medical importance as they protect the microbes
50 from the host's innate immune system (Alhede *et al.* 2009, Bjarnsholt *et al.* 2009), and
51 significantly enhance antimicrobial resistance, with biofilms being 100-1000 times more
52 resistant to antimicrobial therapies than their planktonic counterparts (Mah and O'Toole 2001).
53 Furthermore, cells dispersed from biofilms exhibit a unique transcription profile (Guilhen *et al.*
54 2016), suggesting that dispersed cells represent a distinct stage which may enhance
55 dissemination and infection progression.

56

57 *P. aeruginosa* is frequently co-isolated from sites of infection with the fungal pathogen *Candida*
58 *albicans* (Doern and Brogden-Torres 1992). These two microbes undergo complex
59 interactions including direct cell-cell interactions, and through the secretion of signalling
60 molecules and metabolites (Fourie and Pohl 2019), the outcome of which is dependent on
61 environmental factors. During biofilm formation, *P. aeruginosa* use the fungal hyphae as a
62 scaffold to enhance the structure, composition and complexity of the biofilm (Hogan and Kolter
63 2002, Brand *et al.* 2008). The presence of *C. albicans* in biofilms enhances antibiotic tolerance
64 of several important bacterial pathogens, including *P. aeruginosa* (Harriott and Noverr 2009,
65 Kong *et al.* 2016, Alam *et al.* 2020). Enhanced antimicrobial resistance is hypothesised to
66 result from increased extracellular matrix production in dual species biofilms, as a result of the
67 fungus contributing cell wall carbohydrates like glucans and mannans to the matrix (Harriott
68 and Noverr 2009, De Brucker *et al.* 2015, Kong *et al.* 2016, Alam *et al.* 2020). These fungal
69 polysaccharides are thought to provide protection against antimicrobial agents through either
70 limiting the diffusion of the antimicrobial through the biofilm (i.e. vancomycin) (Kong *et al.*
71 2016), or by binding and sequestering the drugs (i.e. azoles) (Nett *et al.* 2007, Mitchell *et al.*
72 2015).

73

74 Meropenem is a carbapenem antibiotic that is frequently used to treat chronic *P. aeruginosa*
75 infections. Previously we have shown that in dual species biofilms *C. albicans* increases the
76 tolerance of *P. aeruginosa* to meropenem, a process dependent on fungal mannan (Alam *et*
77 *al.* 2020). To provide more detail on the molecular mechanism(s) underlying this phenomenon,
78 we analysed the transcriptional response of mature *P. aeruginosa* biofilms, and dual species
79 biofilms in the absence and presence of meropenem. The transcriptional profile identifies key

80 *P. aeruginosa* genes and biological processes required for resistance to meropenem. Similar
81 genes and processes were unregulated by *P. aeruginosa* in dual species biofilms indicating
82 that the presence of *C. albicans* in mature biofilms does not perturb the *P. aeruginosa*
83 transcriptional response to meropenem.

84

85 **Methods**

86 **Strains and Media**

87 *C. albicans* SC5314 was grown and maintained on yeast peptone dextrose (YPD, Sigma)
88 media, while *P. aeruginosa* PAO1 (ATCC15692) was grown and maintained on LB medium.
89 All biofilm assays were performed in Muller-Hinton broth (MHB).

90

91 **Biofilm assay**

92 Biofilm assays were based on previously described methodology (Alam *et al.* 2020), but
93 scaled up to 6-well plates. In brief, overnight cultures of *C. albicans* and *P. aeruginosa* were
94 washed in PBS, and *C. albicans* resuspended at 1×10^6 cells/ml and *P. aeruginosa* to OD600
95 of 0.2 ($\sim 2 \times 10^8$ CFU/ml) in Mueller-Hinton broth. Each well contained 3 ml *C. albicans* and 300
96 μ l of *P. aeruginosa* in a total of 6 ml. Plates were incubated at 37°C for 2 hr to allow cells to
97 adhere, at which point the media was replaced with fresh sterile media, and plates incubated
98 statically at 37°C for 24 hrs. Cells not part of the biofilm were removed and media replaced
99 with fresh MHB containing 0 or 5 μ g/ml meropenem, and plates incubated for 4 hrs. Media
100 was replaced with 2 ml PBS containing 50 μ g/ml DNase I and plates incubated at 37°C for 1
101 hr to degrade the extracellular matrix. Biofilms were detached from the plate by scraping,
102 serially diluted, and plated onto selective agar (YPD agar supplemented with 100 μ g/ml
103 tetracycline to determine viable *C. albicans* CFUs and Cetrimide agar to determine viable *P.*
104 *aeruginosa* CFUs).

105

106 **Preparation of samples for RNA extraction**

107 Biofilms were formed as described above and triplicate biofilms were pool and 50 μ l serially
108 diluted and plated on cetrimide agar or YPD supplemented with 100 μ g/ml tetracycline to
109 check for contamination. Remaining biofilm cells were centrifuged at 3500 rpm at 4°C for 5
110 min and pellets snap frozen in liquid nitrogen. Four biological replicates were shipped to
111 GeneWiz®, UK, for RNA extraction sequencing and basic bioinformatic analysis.

112

113 **RNA extraction and sequencing**

114 RNA was extracted from the biofilms by GeneWiz® using the Qiagen RNeasy Plus mini kit.
115 Library preparation was done in the following stages: A) ribosomal RNA depletion; B) RNA

116 fragmentation and random priming; C) first and second strand cDNA synthesis; D) end repair,
117 5' phosphorylation and dA-tailing; E) adapter ligation, PCR enrichment and sequencing.
118 Paired-end sequencing was performed using Illumina HiSeq 4000 (2x150bp configuration,
119 single index, per lane).

120

121 **Bioinformatic analysis**

122 Sequence quality of each sample was evaluated by determination of the number of reads, the
123 yield (Mbases), the mean quality score, and the percentage of reads over 30 bases in length.
124 FastQC software was used to determine per base sequence quality and per sequence GC
125 content. Sequence reads were trimmed to remove adapter sequences and nucleotides with
126 poor quality, using Trimmomatic v.0.36. The trimmed reads were mapped to the *P. aeruginosa*
127 reference genome, available on ENSEMBL, using the STAR aligner v.2.5.2b. For dual species
128 biofilms, samples were treated the same as single species biofilms. Reads were mapped to
129 the PAO1 genome, and non-mapped reads were discarded and later aligned to the *C. albicans*
130 reference genome. Unique gene hit counts were calculated using featureCounts from the
131 Subread package v.1.5.2. Only unique reads that fell within exonic regions were counted (for
132 unique genes, the number of hits per read was set to 10 as default, with reads that mapped
133 to less than 10 distinct places be assigned to one place by the EM algorithm, and reads that
134 mapped to more than 10 distinct places being discarded). For the analysis, only read counts
135 for genes in the *P. aeruginosa* genome were used and the TPM values calculated as follows:
136 each read count was divided by the length of each gene in Kb to generate reads per kb (RPK),
137 then all the RPK values in the sample were counted and divided by 1,000,000 to generate the
138 scaling factor, and finally the RPK values were divided by the scaling factor to generate the
139 TPM value. Differential gene expression analysis was performed using DESeq2 and the
140 comparisons listed in Table 1. Principal component analysis (PCA) was performed to reveal
141 the similarities within and between groups, with PCA plots included in the output (Figure S1).
142 As expected, dual species biofilms exhibited greater biological variation than single species
143 biofilms (Figure S1), which likely reflects the heterogeneity of the biofilm structure. Meropenem
144 treatment had the greatest effect on the bacteria transcriptome, with samples clustering into
145 distinct groups in the PCA plots, while *C. albicans* had a reduced impact on the *P. aeruginosa*
146 transcriptome, resulting in great spread of the data. DESeq2 output files for each comparison,
147 and files containing summary raw and normalised reads and TPM values for each gene are
148 available at the Gene Expression Omnibus (GEO) database
149 (<https://www.ncbi.nlm.nih.gov/geo/>), under accession number GSE167137.

150

151 **Enrichment analysis**

152 For *P. aeruginosa* transcriptomic analysis, differential expression of genes between conditions
153 was considered significant if the adjusted P-value (P_{adj}) was ≤0.05. Gene ontology (GO)
154 analysis was done using KOBAS 3.0 software (KEGG (Kyoto Encyclopaedia of Genes and
155 Genomes) Orthology Based Annotation System) (Xie *et al.* 2011).

156

157 **Statistical analysis**

158 Biofilm data were analysed in GraphPad Prism (version 9.1.0) using 2-way ANOVA and Holm-
159 Sidak's multiple comparisons test.

160

161 **Results**

162 ***C. albicans* enhances the tolerance of *P. aeruginosa* biofilms to meropenem even at 163 early timepoints.**

164

165 Previously we have observed that when *P. aeruginosa* is grown in a dual species biofilm with
166 the fungal pathogen *C. albicans*, the tolerance of *P. aeruginosa* to meropenem is increased
167 (Alam *et al.* 2020). To understand the molecular mechanism(s) behind this increased
168 tolerance transcriptional profiling was performed. To avoid the transcriptional profile focusing
169 on genes related to cell death, we analysed the transcriptome after the antibiotic had been
170 added to mature biofilms for 4 hours. Plating of mono and dual species biofilms in the absence
171 and presence of meropenem confirmed that the majority of the cell population was viable at
172 this time point. Furthermore, the tolerance of *P. aeruginosa* to meropenem in the presence of
173 *C. albicans* was still enhanced even at this early timepoint (Figure 1).

174

175

176 **Meropenem enhances *ampC* expression in *P. aeruginosa* single species biofilms**

177 Addition of meropenem to *P. aeruginosa* mono species biofilms resulted in the significant
178 upregulation of 354 genes, while 509 genes were downregulated (Figure 2, Figure S2A, Table
179 2). Of the significantly differentially regulated genes 45% (159/354) and 43% (217/509)
180 encoded hypothetical proteins. As expected, the most significantly up regulated gene in
181 response to meropenem treatment was *ampC* (log₂ fold change = 7.75, P_{adj} = 1.95 10⁻⁴²),
182 which encodes a beta-lactamase, important for carbapenem resistance. GO term enrichment
183 analysis of the differentially regulated genes confirmed that meropenem resulted in the
184 significant upregulation of genes involved in the maintenance of the bacterial cell membrane,
185 cell wall, biofilm formation and extracellular matrix production, siderophore production, type IV
186 pilus formation, and type VI secretion system, while genes involved in putrescine transport
187 were significantly downregulated (Figure 3A). KEGG pathway analysis, identified the over
188 representation of genes involved in siderophore biosynthesis, vancomycin resistance, amino
189 acid metabolism, biofilm formation and bacterial secretion in genes that were significantly up

190 regulated and pathways associated with thiamine metabolism, mismatch repair, pyrimidine
191 metabolism, and purine metabolism were significantly down regulated (Figure 3B).

192

193 **The presence of *C. albicans* in dual species biofilms results in mild changes in the *P.***
194 ***aeruginosa* transcriptome.**

195 To determine how the presence of *C. albicans* affected *P. aeruginosa*, we compared the
196 transcriptional profile of *P. aeruginosa* single species biofilms to dual species biofilms. The
197 presence of *C. albicans* resulted in the differential regulation of 392 genes, with 265 genes
198 being significantly upregulated and 127 genes being significantly down regulated (Figure 2,
199 Figure S2B, Table 3). Although significant, we note that the \log_2 values for the majority of
200 these genes was less than 1, suggesting that *C. albicans* has a mild impact on the transcription
201 profile of *P. aeruginosa*. The most significantly differentially regulated genes were PA4097 (a
202 lipolytic protein) and PA5384 (an alcohol dehydrogenase) which were both 2-fold upregulated
203 in the presence of *C. albicans*. GO term enrichment analysis (Figure 4A), and KEGG pathway
204 analysis (Figure 4B) of the 392 differentially regulated genes identified that phenazine
205 biosynthesis, *Pseudomonas* quinolone signal (PQS) production, pyridocal phosphate
206 biosynthesis, and siderophore transport and pyoverdine biosynthesis were significantly
207 upregulated while genes involved in type IV pilus biogenesis, the general secretory (Sec)
208 pathway, and amino acid biosynthesis were significantly down regulated. Therefore, *P.*
209 *aeruginosa* appears to upregulate processes that might provide the bacterium with a
210 competitive advantage when growing in the presence of *C. albicans*.

211

212 To identify whether the presence of the fungus was inducing a similar transcriptional response
213 to the drug treatment we compared DEGs identified in *P. aeruginosa* single species biofilms
214 treated with meropenem to the list of DEGs identified in untreated dual species biofilms. Seven
215 genes (PA10907, PA4830, PA4518, PA1209, *rimK*, PA0881 and PA3758) were upregulated,
216 while five genes (*pyrD*, *aroC*, PA4633, PA3526 and PA4637) were down regulated under both
217 conditions. However, as the majority of the genes encode hypothetical proteins the impact of
218 these transcriptional responses is unknown.

219

220 **Impact of *C. albicans* on the *P. aeruginosa* transcriptional response to meropenem**

221 To determine whether the presence of *C. albicans* affected the response of *P. aeruginosa* to
222 meropenem, we compared the transcriptional profile of untreated dual species biofilms to
223 meropenem treated dual species biofilms. In response to meropenem, a total of 620 genes
224 were differentially regulated, with 304 genes being significantly upregulated, and 316 being
225 significantly downregulated (Figure 2, Figure S2C, Table 4). As was the case for the single
226 species biofilms, *ampC* was the most significantly upregulated gene ($\log_2 = 5.52$, $P_{adj} = 1.95$

227 10⁻⁴⁷). GO term enrichment analysis (Figure 5A) and KEGG pathway analysis (Figure 5B)
228 confirmed that like single species biofilms, treatment of *P. aeruginosa* dual species biofilms
229 with meropenem resulted in the upregulation of genes involved in cell division, peptidoglycan
230 biosynthesis, biofilm formation, extracellular matrix production siderophore biosynthesis and
231 type VI secretion. Likewise, the processes that were significantly downregulated in single
232 species biofilms in response to meropenem (i.e. putrescine transport and mismatch repair)
233 where shared with dual species biofilms (Figure 5).

234

235 Although *C. albicans* does not affect the general processes that are differentially regulated in
236 response to meropenem, it is possible that the underlying DEGs are different. Therefore, we
237 compared the DEGs between single and dual species biofilms in response to meropenem. Of
238 the genes that were significantly upregulated in response to meropenem, 181 (37.9%) were
239 upregulated in both single and dual species biofilms, while 173 (36.3%) and 123 (25.8%) were
240 unique to single, and dual species biofilms, respectively (Figure 6A). Among the upregulated
241 genes that were unique to the dual-species meropenem response, there were three linked to
242 outer membrane vesicles (*pagL*, *galU* and PA5441) (Choi *et al.* 2011), one involved in cell wall
243 synthesis (*ddlA*), three involved in biofilm formation (*pslH*, *pslI* and *algR*), and three involved
244 in efflux (PA1809, *mexC* and PA3314). This suggests that the presence of *C. albicans* may
245 increase the ability of *P. aeruginosa* to form robust biofilms, to secrete molecules via outer
246 membrane vesicles (OMVs) and the MexCD-OprJ efflux pump, which may play a role in
247 increasing the tolerance of the bacterium to meropenem.

248

249 Of the genes that were significantly downregulated in response to meropenem, 282 (51.9%)
250 genes were shared in common between single and dual species *P. aeruginosa* biofilm cells,
251 while 227 (41.8%) and 34 (6.3%) were unique to single and dual species biofilms respectively,
252 (Figure 6B). Among the few downregulated genes that were unique to the dual-species
253 meropenem response, there were six involved in efflux or membrane transport (PA0603,
254 PA0604, *mexE*, *mexF*, PA0860 and PA1051). This suggests that the presence of *C. albicans*
255 may result in reduced production of the MexEF-OprN efflux pump in *P. aeruginosa* biofilm
256 cells.

257

258 **Discussion**

259 Biofilms are medically important as they result in antimicrobial resistance and protect microbes
260 from the actions of the immune system, making infection harder to treat. Furthermore, biofilms
261 are normally mixed species communities, with our understanding of how microbe-microbe
262 interactions within these communities affect disease progression being limited. We have
263 previously shown that *C. albicans* enhances the tolerance of *P. aeruginosa* to meropenem, a

264 commonly used carbapenem for the treatment of chronic *P. aeruginosa* infections. Therefore,
265 transcriptional analysis was carried out to understand how *C. albicans* promotes meropenem
266 tolerance.

267

268 Mechanisms of resistance to the carbapenem class of antibiotics include decreased outer
269 membrane permeability, beta-lactamase expression, increased efflux and target modification.
270 In agreement with this, the addition of meropenem to mature *P. aeruginosa* single species
271 biofilms resulted in the significant induction of *ampC*, a beta lactamase precursor. Differential
272 regulation of *ampC* is linked to the natural resistance of *P. aeruginosa* to this class of antibiotic
273 (Khaledi *et al.* 2016). Imipenem, another carbapenem use to treat *P. aeruginosa* infections,
274 also induces the expression of *ampC* (Bagge *et al.* 2004), highlighting *ampC* induction as a
275 conserved response to carbapenems. In addition to *ampC*, the outer membrane porin, OprD,
276 has also been associated with meropenem resistance. OprD facilitates entry of carbapenems
277 into bacterial cells, and is therefore frequently downregulated in meropenem-resistant strains
278 (Khaledi *et al.* 2016). In our study, *oprD* was not differentially regulated in response to
279 meropenem treatment. However, there is often a poor correlation between *oprD* mRNA levels
280 and protein levels (Khaledi *et al.* 2016). Therefore, it is possible that OprD protein levels are
281 downregulated in our biofilms to reduce meropenem uptake.

282

283 Interestingly, treatment of *P. aeruginosa* biofilms with either meropenem or imipenem, results
284 in the significant induction of biofilm associated genes (Bagge *et al.* 2004). For example, in
285 response to meropenem extracellular polysaccharide biosynthetic genes like *pslB*, *pslD*, *pslE*
286 and *pslF* were significantly upregulated. The induction of these polysaccharide genes results
287 in enhanced intracellular and cell-substrate interactions, and the expression of subsets of
288 these genes are commonly enhanced in biofilm forming clinical isolates. Psl is thought to
289 enhance the tolerance of *P. aeruginosa* biofilms to a range of antimicrobial agents including
290 colistin, tobramycin and ciprofloxacin (Billings *et al.* 2013).

291

292 In response to meropenem, genes involved in the Type 6 secretion system (T6SS) were also
293 significantly upregulated including *ppkA*, *pppA*, *clpV1*, *icmF1*, *vgrG1* and *hcp1*. The structure
294 of the T6SS bears similarities to the cell-puncturing needle of bacteriophage viruses; the roles
295 of the T6SS in *P. aeruginosa* include virulence within hosts, delivery of toxins to neighbouring
296 microbes that are competing for resources, and biofilm formation (Chen *et al.* 2015, Chen *et al.*
297 *et al.* 2020). Although there has been no previous research linking antibiotic treatment to
298 upregulation of T6SS activity in *P. aeruginosa*, the T6SS has been implicated in drug
299 resistance in *A. baumannii* and *K. pneumoniae* (Liu *et al.* 2017, Wang *et al.* 2018). However,
300 in *P. aeruginosa*, the T6SS is upregulated during competition with other bacteria as a result

301 of kin cell lysis (LeRoux *et al.* 2015). Therefore, it is possible that the observed increase in
302 transcription of components of the T6SS is a result of meropenem induced cell lysis.

303

304 During growth in dual species biofilms, *P. aeruginosa* upregulates genes required for quorum
305 sensing, with all genes from the *pqsABCDE* operon being significantly upregulated. The *pqs*
306 operon encodes several enzymes required for production of the *Pseudomonas* quinolone
307 signal (PQS) (Higgins *et al.* 2018). *C. albicans* dependent regulation of PQS production is
308 complex. The fungal quorum sensing molecule, farnesol, inhibits PQS production in planktonic
309 interactions through modulation of PqsR dependent transcription of the *pqs* operon (Cugini *et*
310 *al.* 2007). However, in *lasR* deficient *P. aeruginosa* strains, *C. albicans* restores PQS
311 production through farnesol induced ROS dependent production of C4-HSL (Cugini *et al.*
312 2010). Increased C4-HSL results in the induction of *pqsH* and therefore restores PQS and
313 phenazine production (Cugini *et al.* 2010). However, PQS is also induced under iron limiting
314 conditions (Oglesby *et al.* 2008), resulting in increased biosynthesis of phenazines and
315 siderophores, which both scavenge iron from the environment.

316

317 Phenazines are redox-active molecules that affect the redox balance of cells, the uptake of
318 metabolites, gene expression, and have also been shown to enhance *P. aeruginosa* tolerance
319 to the antibiotic, ciprofloxacin (Schiesl *et al.* 2019). Phenazines are also able to facilitate
320 electron transfer within biofilms (Saunders *et al.* 2020). Pathways associated with the
321 biosynthesis of these molecules were the most significantly upregulated biological process in
322 our dual species biofilms, and in other studies highlighting their importance in interkingdom
323 interactions.

324

325 Our transcriptional analysis identified several RND and ABC transporters to the differentially
326 regulated in dual species biofilms in the presence of meropenem. little is known about the role
327 of ABC transporters in *P. aeruginosa* drug resistance (Hulen *et al.* 2020), it is clear that the
328 presence of *C. albicans* alters the expression of several efflux pumps, which may contribute
329 to carbapenem tolerance in dual species biofilms. The *P. aeruginosa* genome encodes for at
330 least 12 RND efflux pumps (Scoffone *et al.* 2021), three of which (MexAB-OprM, MexXY-OprM
331 and MexCD-OprJ) have been linked to meropenem resistance (Fusté *et al.* 2013, Hassuna *et*
332 *al.* 2020). MexC was induced in dual species biofilms, in response to meropenem treatment,
333 suggesting that *P. aeruginosa* may increase efflux through MexCD-OprJ. Phenazines and
334 their derivatives have been shown to directly regulate the expression of several efflux pumps
335 including *mexG* (Dietrich *et al.* 2006, Sakhtah *et al.* 2016). Therefore, increased synthesis of
336 phenazines in these biofilms could alter drug efflux and increase the tolerance of *P.*
337 *aeruginosa* to meropenem. In agreement with this, enhanced production of the phenazine,

338 pyocyanin, promotes resistance to the beta-lactam class of antibiotics through reduced drug
339 influx (Zhao *et al.* 2022).

340

341 Other differences between the transcriptional profiles for single and dual species biofilms in
342 response to meropenem include genes involved in biofilm formation (*pslH*, *pslI* and *algR*) and
343 outer membrane vesicles (OMVs). AlgR is a transcriptional regulator of genes involved in
344 alginate production (Deretic *et al.* 1989). Therefore, in addition to enhanced extracellular
345 polysaccharide production through Psl biosynthesis, dual species biofilms will also contain
346 increased levels of alginate. Increased alginate production is known to enhance biofilm
347 production (Bagge *et al.* 2004), but has not been directly linked to antibiotic resistance. OMVs
348 play important roles in biofilms including the secretion of PQS, extracellular DNA and beta-
349 lactamase (Bomberger *et al.* 2009, Florez *et al.* 2017). Therefore, enhance OMV production
350 in the presence of *C. albicans* may function to increase the composition and complexity of the
351 extracellular matrix, which together with enhanced beta-lactamase secretion would increase
352 the tolerance of *P. aeruginosa* to meropenem.

353

354 In summary, in response to meropenem *P. aeruginosa* biofilms upregulate *ampC* and biofilm
355 formation to provide protection from meropenem. Although, dual species biofilms exhibit
356 enhanced tolerance to meropenem, the *P. aeruginosa* transcriptional responses from dual
357 species biofilms exposed to meropenem were similar to single species biofilms treated with
358 meropenem, suggesting that the presence of *C. albicans* in dual species biofilms may limit the
359 diffusion, or sequester the antibiotic leading to increased bacterial tolerance.

360

361 **Conflicts of Interest**

362 The author(s) declare that there are no conflicts of interest.

363

364 **Funding information**

365 Work in the Hall Lab is supported by an MRC Career Development Award (MR/L00903X/1)
366 and the BBSRC (BB/R00966X/1, BB/R00966X/2). Work in the Blair Lab is support via a David
367 Phillips Fellowship to J.M.A.B. (BB/M02623X/1). F.A. is supported by the Wellcome Trust
368 Antimicrobials and Antimicrobial Resistance (AAMR) doctoral training programme
369 (108876/Z/15/Z).

370

371 **Author contributions**

372 RAH and JB conceived and designed the experiments, FA performed the experiments and
373 analysed the data. RAH wrote the manuscript.

374

375 **References**

376 Alam, F., D. Catlow, A. Di Maio, J. M. A. Blair and R. A. Hall (2020). "*Candida albicans*
377 enhances meropenem tolerance of *Pseudomonas aeruginosa* in a dual-species biofilm." J
378 Antimicrob Chemother 75: 925-935.

379 Alhede, M., T. Bjarnsholt, P. Jensen, R. K. Phipps, C. Moser, L. Christophersen, L. D.
380 Christensen, M. van Gennip, M. Parsek, N. Høiby, *et al.* (2009). "*Pseudomonas aeruginosa*
381 recognizes and responds aggressively to the presence of polymorphonuclear leukocytes."
382 Microbiology (Reading) 155: 3500-3508.

383 Bagge, N., M. Schuster, M. Hentzer, O. Ciofu, M. Givskov, E. P. Greenberg and N. Høiby
384 (2004). "*Pseudomonas aeruginosa* biofilms exposed to imipenem exhibit changes in global
385 gene expression and beta-lactamase and alginate production." Antimicrobial Agents and
386 Chemotherapy 48: 1175-1187.

387 Billings, N., M. Millan, M. Caldara, R. Rusconi, Y. Tarasova, R. Stocker and K. Ribbeck (2013).
388 "The extracellular matrix Component Psl provides fast-acting antibiotic defense in
389 *Pseudomonas aeruginosa* biofilms." PLoS Pathog 9: e1003526.

390 Bjarnsholt, T., P. Jensen, M. J. Fiandaca, J. Pedersen, C. R. Hansen, C. B. Andersen, T.
391 Pressler, M. Givskov and N. Høiby (2009). "*Pseudomonas aeruginosa* biofilms in the
392 respiratory tract of cystic fibrosis patients." Pediatr Pulmonol 44: 547-558.

393 Bomberger, J. M., D. P. Maceachran, B. A. Coutermarsh, S. Ye, G. A. O'Toole and B. A.
394 Stanton (2009). "Long-distance delivery of bacterial virulence factors by *Pseudomonas*
395 *aeruginosa* outer membrane vesicles." PLoS pathogens 5: e1000382-e1000382.

396 Brand, A., J. D. Barnes, K. S. Mackenzie, F. C. Odds and N. A. R. Gow (2008). Cell wall
397 glycans and soluble factors determine the interactions between the hyphae of *Candida*
398 *albicans* and *Pseudomonas aeruginosa*.

399 Chatterjee, M., C. P. Anju, L. Biswas, V. Anil Kumar, C. Gopi Mohan and R. Biswas (2016).
400 "Antibiotic resistance in *Pseudomonas aeruginosa* and alternative therapeutic options." Int J
401 Med Microbiol 306: 48-58.

402 Chen, L., Y. Zou, A. A. Kronfl and Y. Wu (2020). "Type VI secretion system of *Pseudomonas*
403 *aeruginosa* is associated with biofilm formation but not environmental adaptation."
404 Microbiologyopen 9: e991.

405 Chen, L., Y. Zou, P. She and Y. Wu (2015). "Composition, function, and regulation of T6SS in
406 *Pseudomonas aeruginosa*." Microbiol Res 172: 19-25.

407 Choi, D.-S., D.-K. Kim, S. J. Choi, J. Lee, J.-P. Choi, S. Rho, S.-H. Park, Y.-K. Kim, D. Hwang
408 and Y. S. Gho (2011). "Proteomic analysis of outer membrane vesicles derived from
409 *Pseudomonas aeruginosa*." PROTEOMICS 11: 3424-3429.

410 Cugini, C., M. W. Calfee, J. M. Farrow, 3rd, D. K. Morales, E. C. Pesci and D. A. Hogan (2007).
411 "Farnesol, a common sesquiterpene, inhibits PQS production in *Pseudomonas aeruginosa*."
412 Mol Microbiol 65: 896-906.

413 Cugini, C., D. K. Morales and D. A. Hogan (2010). "*Candida albicans*-produced farnesol
414 stimulates *Pseudomonas* quinolone signal production in LasR-defective *Pseudomonas*
415 *aeruginosa* strains." Microbiology (Reading, England) 156: 3096-3107.

416 Deretic, V., R. Dikshit, W. M. Konyecsni, A. M. Chakrabarty and T. K. Misra (1989). "The *algR*
417 gene, which regulates mucoidy in *Pseudomonas aeruginosa*, belongs to a class of
418 environmentally responsive genes." J Bacteriol 171: 1278-1283.

419 Dietrich, L. E. P., A. Price-Whelan, A. Petersen, M. Whiteley and D. K. Newman (2006). "The
420 phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of
421 *Pseudomonas aeruginosa*." Molecular Microbiology 61: 1308-1321.

422 Doern, G. V. and B. Brogden-Torres (1992). "Optimum use of selective plated media in
423 primary processing of respiratory tract specimens from patients with Cystic Fibrosis." Journal
424 Clinical Microbiology 30: 2740-2742.

425 Fazli, M., T. Bjarnsholt, K. Kirketerp-Møller, B. Jørgensen, A. S. Andersen, K. A. Krogfelt, M.
426 Givskov and T. Tolker-Nielsen (2009). "Nonrandom distribution of *Pseudomonas aeruginosa*
427 and *Staphylococcus aureus* in chronic wounds." J Clin Microbiol 47: 4084-4089.

428 Florez, C., J. E. Raab, A. C. Cooke and J. W. Schertzer (2017). "Membrane Distribution of the
429 *Pseudomonas* Quinolone Signal Modulates Outer Membrane Vesicle Production in
430 *Pseudomonas aeruginosa*." mBio 8: e01034-01017.

431 Fourie, R. and C. H. Pohl (2019). "Beyond Antagonism: The Interaction Between *Candida*
432 Species and *Pseudomonas aeruginosa*." Journal of fungi (Basel, Switzerland) 5: 34.

433 Fusté, E., L. López-Jiménez, C. Segura, E. Gainza, T. Vinuesa and M. Viñas (2013).
434 "Carbapenem-resistance mechanisms of multidrug-resistant *Pseudomonas aeruginosa*." J
435 Med Microbiol 62: 1317-1325.

436 Guilhen, C., N. Charbonnel, N. Parisot, N. Gueguen, A. Iltis, C. Forestier and D. Balestrino
437 (2016). "Transcriptional profiling of *Klebsiella pneumoniae* defines signatures for planktonic,
438 sessile and biofilm-dispersed cells." BMC Genomics 17: 237.

439 Harriott, M. M. and M. C. Noverr (2009). "*Candida albicans* and *Staphylococcus aureus* form
440 polymicrobial biofilms: effects on antimicrobial resistance." Antimicrob Agents Chemother 53:
441 3914-3922.

442 Hassuna, N. A., M. K. Darwish, M. Sayed and R. A. Ibrahim (2020). "Molecular Epidemiology
443 and Mechanisms of High-Level Resistance to Meropenem and Imipenem in *Pseudomonas*
444 *aeruginosa*." Infect Drug Resist 13: 285-293.

445 Higgins, S., S. Heeb, G. Rampioni, M. P. Fletcher, P. Williams and M. Cámara (2018).
446 "Differential Regulation of the Phenazine Biosynthetic Operons by Quorum Sensing in
447 *Pseudomonas aeruginosa* PAO1-N." *Front Cell Infect Microbiol* 8: 252.

448 Hogan, D. A. and R. Kolter (2002). "*Pseudomonas-Candida* interactions: an ecological
449 role for virulence factors." *Science* 296: 2229-2232.

450 Hulen, C., P.-J. Racine, S. Chevalier, M. Feuilloley and N.-E. Lomri (2020). "Identification of
451 the PA1113 Gene Product as an ABC Transporter Involved in the Uptake of Carbenicillin in
452 *Pseudomonas aeruginosa* PAO1." *Antibiotics* (Basel, Switzerland) 9: 596.

453 Khaledi, A., M. Schniederjans, S. Pohl, R. Rainer, U. Bodenhofer, B. Xia, F. Klawonn, S.
454 Bruchmann, M. Preusse, D. Eckweiler, *et al.* (2016). "Transcriptome Profiling of Antimicrobial
455 Resistance in *Pseudomonas aeruginosa*." *Antimicrob Agents Chemother* 60: 4722-4733.

456 Kong, E. F., C. Tsui, S. Kucharíková, D. Andes, P. Van Dijck and M. A. Jabra-Rizk (2016).
457 "Commensal Protection of *Staphylococcus aureus* against Antimicrobials by *Candida albicans*
458 Biofilm Matrix." *mBio* 7.

459 LeRoux, M., R. L. Kirkpatrick, E. I. Montauti, B. Q. Tran, S. B. Peterson, B. N. Harding, J. C.
460 Whitney, A. B. Russell, B. Traxler, Y. A. Goo, *et al.* (2015). "Kin cell lysis is a danger signal
461 that activates antibacterial pathways of *Pseudomonas aeruginosa*." *Elife* 4.

462 Liu, L., M. Ye, X. Li, J. Li, Z. Deng, Y. F. Yao and H. Y. Ou (2017). "Identification and
463 Characterization of an Antibacterial Type VI Secretion System in the Carbapenem-Resistant
464 Strain *Klebsiella pneumoniae* HS11286." *Front Cell Infect Microbiol* 7: 442.

465 Lyczak, J. B., C. L. Cannon and G. B. Pier (2002). "Lung infections associated with Cystic
466 Fibrosis." *Clin Microbiol Rev* 15: 194-222.

467 Mah, T. F. and G. A. O'Toole (2001). "Mechanisms of biofilm resistance to antimicrobial
468 agents." *Trends Microbiol* 9: 34-39.

469 Mitchell, K. F., R. Zarnowski, H. Sanchez, J. A. Edward, E. L. Reinicke, J. E. Nett, A. P. Mitchell
470 and D. R. Andes (2015). "Community participation in biofilm matrix assembly and function."
471 *Proc Natl Acad Sci U S A* 112: 4092-4097.

472 Nett, J., L. Lincoln, K. Marchillo, R. Massey, K. Holoyda, B. Hoff, M. VanHandel and D. Andes
473 (2007). "Putative Role of beta-1,3 Glucans in *Candida albicans* Biofilm Resistance."
474 *Antimicrobial Agents and Chemotherapy* 51: 510-520.

475 Oglesby, A. G., J. M. Farrow, 3rd, J. H. Lee, A. P. Tomaras, E. P. Greenberg, E. C. Pesci and
476 M. L. Vasil (2008). "The influence of iron on *Pseudomonas aeruginosa* physiology: a
477 regulatory link between iron and quorum sensing." *J Biol Chem* 283: 15558-15567.

478 Ramakrishnan, M., S. Putli Bai and M. Babu (2016). "Study on biofilm formation in burn wound
479 infection in a pediatric hospital in Chennai, India." *Ann Burns Fire Disasters* 29: 276-280.

480 Sakhtah, H., L. Koyama, Y. Zhang, D. K. Morales, B. L. Fields, A. Price-Whelan, D. A. Hogan,
481 K. Shepard and L. E. Dietrich (2016). "The *Pseudomonas aeruginosa* efflux pump MexGHI-
482 OpmD transports a natural phenazine that controls gene expression and biofilm
483 development." *Proc Natl Acad Sci U S A* 113: E3538-3547.

484 Saunders, S. H., E. C. M. Tse, M. D. Yates, F. J. Otero, S. A. Trammell, E. D. A. Stemp, J. K.
485 Barton, L. M. Tender and D. K. Newman (2020). "Extracellular DNA Promotes Efficient
486 Extracellular Electron Transfer by Pyocyanin in *Pseudomonas aeruginosa* Biofilms." *Cell* 182:
487 919-932.e919.

488 Schiessl, K. T., F. Hu, J. Jo, S. Z. Nazia, B. Wang, A. Price-Whelan, W. Min and L. E. P.
489 Dietrich (2019). "Phenazine production promotes antibiotic tolerance and metabolic
490 heterogeneity in *Pseudomonas aeruginosa* biofilms." *Nat Commun* 10: 762.

491 Scoffone, V. C., G. Trespidi, G. Barbieri, S. Irudal, E. Perrin and S. Buroni (2021). "Role of
492 RND Efflux Pumps in Drug Resistance of Cystic Fibrosis Pathogens." *Antibiotics* 10: 863.

493 Wang, J., Z. Zhou, F. He, Z. Ruan, Y. Jiang, X. Hua and Y. Yu (2018). "The role of the type
494 VI secretion system *vgrG* gene in the virulence and antimicrobial resistance of *Acinetobacter*
495 *baumannii* ATCC 19606." *PLoS One* 13: e0192288.

496 Xie, C., X. Mao, J. Huang, Y. Ding, J. Wu, S. Dong, L. Kong, G. Gao, C. Y. Li and L. Wei
497 (2011). "KOBAS 2.0: a web server for annotation and identification of enriched pathways and
498 diseases." *Nucleic Acids Res* 39: 316-322.

499 Zhao, X., Y. Jin, F. Bai, Z. Cheng, W. Wu and X. Pan (2022). "Mutation of *PA4292* in
500 *Pseudomonas aeruginosa* Increases beta-Lactam Resistance through Upregulating
501 Pyocyanin Production." *Antimicrobial Agents and Chemotherapy* 66: e00421-00422.

502 Wang, J., Z. Zhou, F. He, Z. Ruan, Y. Jiang, X. Hua and Y. Yu (2018). "The role of the type
503 VI secretion system *vgrG* gene in the virulence and antimicrobial resistance of *Acinetobacter*
504 *baumannii* ATCC 19606." *PLoS One* 13: e0192288.

505 Zhao, X., Y. Jin, F. Bai, Z. Cheng, W. Wu and X. Pan (2022). "Mutation of *PA4292* in
506 *Pseudomonas aeruginosa* Increases beta-Lactam Resistance through Upregulating
507 Pyocyanin Production." *Antimicrobial Agents and Chemotherapy* 0: e00421-00422.

508
509
510
511
512
513
514
515
516

517 **Table 1. Differential expression analysis carried out by DESeq2**

Comparison	Abbreviation	vs	Output file
Untreated <i>P. aeruginosa</i> mono-species biofilm vs <i>P. aeruginosa</i> mono-species treated with 5 µg/mL meropenem	PA_0M PA_5M		P_aeruginosa_expression_ PA_0M_vs_PA_5M.xlsx
Untreated <i>P. aeruginosa</i> mono-species biofilm vs dual species biofilms	PA_0M PACA_0M		P_aeruginosa_expression_ PA_0M_vs_PACA_0M.xlsx
Untreated <i>P. aeruginosa</i> mono-species biofilms vs dual species biofilms treated with 5 µg/mL meropenem	PACA_0M PACA_5M		P_aeruginosa_expression_ PACA_0M_vs_PACA_5M.xlsx

518

519

520 **Table 2. Top twenty differentially regulated genes in *P. aeruginosa* untreated single**
 521 **biofilms vs single species biofilms treated with 5 µg/mL meropenem.**

	Gene ID	log2 Fold Change	p-value	padj
Upregulated	<i>ampC</i>	5.745634677	3.54E-46	1.95E-42
	<i>PA4111</i>	3.141752798	2.08E-25	1.27E-22
	<i>hcp1</i>	2.299594301	9.57E-20	2.64E-17
	<i>PA0126</i>	2.010278388	4.77E-15	6.75E-13
	<i>clpV1</i>	1.832477469	5.89E-09	3.65E-07
	<i>PA4280.2</i>	1.825681731	0.0007200374797	0.008213485384
	<i>PA0084</i>	1.81927681	9.59E-07	3.60E-05
	<i>PA0083</i>	1.812545239	2.64E-06	8.69E-05
	<i>PA4690.2</i>	1.811643426	0.0006939310453	0.00798165271
	<i>PA5369.2</i>	1.811071763	0.0007048977579	0.008057433792
	<i>PA0668.4</i>	1.770903731	0.0005529877155	0.006709989401
	<i>PA0070</i>	1.759966355	2.86E-06	9.28E-05
	<i>PA0277</i>	1.706435238	2.22E-11	2.04E-09
	<i>vgrG1</i>	1.692796239	4.23E-08	2.12E-06
	<i>PA0466</i>	1.68245735	3.45E-06	0.0001075909918
	<i>PA0089</i>	1.645610422	8.37E-08	3.89E-06
	<i>PA0050</i>	1.596317219	3.73E-05	0.0007623159776
	<i>rplX</i>	1.577791178	0.003955658099	0.03020634629

	<i>rpsQ</i>	1.514302023	0.003135531829	0.0252719288
	<i>rplN</i>	1.482472974	0.006174262969	0.04190492586
Downregulated	<i>PA0627</i>	-2.563807744	7.94E-27	6.26E-24
	<i>PA0629</i>	-2.554150934	7.27E-33	1.34E-29
	<i>PA0641</i>	-2.55319332	1.46E-27	1.34E-24
	<i>PA0628</i>	-2.534582315	1.07E-31	1.47E-28
	<i>PA0638</i>	-2.46361566	3.36E-33	9.27E-30
	<i>PA0636</i>	-2.444427878	2.44E-22	1.04E-19
	<i>PA0635</i>	-2.415846681	1.41E-22	6.50E-20
	<i>gfnR</i>	-2.353411699	6.68E-14	8.58E-12
	<i>PA0630</i>	-2.310960008	2.67E-21	8.68E-19
	<i>PA0639</i>	-2.28619203	5.70E-25	2.86E-22
	<i>PA3638</i>	-2.285364587	4.83E-11	4.17E-09
	<i>PA0634</i>	-2.272274644	9.09E-19	2.09E-16
	<i>PA1168</i>	-2.27006418	2.26E-06	7.65E-05
	<i>PA0637</i>	-2.231450235	9.63E-22	3.80E-19
	<i>PA0616</i>	-2.222013132	1.13E-25	7.79E-23
	<i>PA0625</i>	-2.213888097	1.84E-21	6.78E-19
	<i>ptrB</i>	-2.203953211	6.10E-17	1.05E-14
	<i>PA0631</i>	-2.195277667	2.16E-20	6.63E-18
	<i>PA0613</i>	-2.187796631	4.07E-18	8.32E-16
	<i>PA0618</i>	-2.143020354	3.73E-18	7.91E-16

522

523

524

525

Table 3. Top twenty differentially regulated *P. aeruginosa* genes in dual species versus single species biofilms

	Gene ID	log2 Fold Change	p-value	padj
Upregulated	<i>PA5384</i>	1.136608573	4.28E-06	0.0002779376198
	<i>PA4097</i>	1.000660434	3.17E-05	0.001214321657
	<i>cdhB</i>	0.9811955186	5.21E-06	0.0003198899691
	<i>PA2161</i>	0.9810583138	0.0003525619038	0.008808371695
	<i>cdhC</i>	0.936864827	9.18E-07	7.92E-05
	<i>cdhA</i>	0.9176339588	1.17E-09	4.57E-07
	<i>ssrS</i>	0.9064141369	8.59E-13	6.76E-10
	<i>PA0698</i>	0.9014266847	1.42E-05	0.0006654679167

	<i>PA2349</i>	0.8950640392	2.59E-05	0.001067775173
	<i>PA2181</i>	0.8814108328	9.08E-08	1.36E-05
	<i>PA2090</i>	0.8800287264	1.03E-07	1.50E-05
	<i>PA2324</i>	0.867636224	1.23E-05	0.0005976988392
	<i>PA2213</i>	0.8532908266	7.35E-16	1.35E-12
	<i>PA2180</i>	0.8294884121	1.24E-09	4.57E-07
	<i>PA4088</i>	0.8176661995	7.06E-09	1.77E-06
	<i>czcC</i>	0.8158365062	9.15E-08	1.36E-05
	<i>phzC2</i>	0.7984412293	3.58E-07	4.21E-05
	<i>phzC1</i>	0.788317377	3.04E-05	0.00117677973
	<i>PA4098</i>	0.7866314328	0.0005949449343	0.01341483781
	<i>phzA1</i>	0.7731714023	4.59E-06	0.0002943805348
Downregulated	<i>PA3572</i>	-0.9273548369	0.003059228691	0.0450911657
	<i>argB</i>	-0.8972467441	3.86E-09	1.02E-06
	<i>rnpB</i>	-0.8480655754	3.66E-08	5.77E-06
	<i>PA1746</i>	-0.7808094482	2.35E-05	0.0009898437811
	<i>PA4351</i>	-0.7261070956	2.78E-05	0.00110592551
	<i>PA5303</i>	-0.6697670409	3.36E-13	3.09E-10
	<i>ftsY</i>	-0.5672143027	1.04E-08	2.29E-06
	<i>PA4276.1</i>	-0.5616231924	1.53E-05	0.0006970521393
	<i>PA4690.3</i>	-0.5391253382	0.002180107776	0.03467439429
	<i>PA1137</i>	-0.5377222343	1.98E-11	9.95E-09
	<i>PA3133.3</i>	-0.5289323628	0.0003527179099	0.008808371695
	<i>ssrA</i>	-0.5226447106	3.43E-06	0.0002369715977
	<i>PA3573</i>	-0.5188361793	6.23E-05	0.002219824419
	<i>PA4421</i>	-0.5151637325	1.87E-11	9.95E-09
	<i>PA1796.1</i>	-0.4988013205	0.001465215919	0.02591835467
	<i>PA4637</i>	-0.4958503362	0.001596304616	0.02744549898
	<i>PA1510</i>	-0.4875966167	3.42E-08	5.55E-06
	<i>PA3951</i>	-0.4870639148	9.51E-09	2.25E-06
	<i>PA2943</i>	-0.4748718073	1.76E-06	0.0001407992501
	<i>PA3277</i>	-0.4616098795	0.0007070580094	0.01530295354

526

527

528 **Table 4. Top twenty differentially regulated *P. aeruginosa* genes in dual species**529 **biofilms treated with 5 µg/mL meropenem vs untreated dual species biofilms.**

	Gene ID	log2 Fold Change	p-value	padj
Upregulated	<i>ampC</i>	5.515387278	7.06E-51	1.95E-47
	<i>PA4280.5</i>	3.700797106	7.82E-06	0.0002259666295
	<i>PA0668.1</i>	3.67825942	8.05E-06	0.0002315796869
	<i>PA4690.5</i>	3.49778215	2.92E-05	0.0007129969543
	<i>PA5369.5</i>	3.485074044	3.01E-05	0.0007281076683
	<i>PA4111</i>	2.963866877	8.30E-18	1.99E-15
	<i>PA4690.2</i>	2.605990986	0.003138749477	0.03261549984
	<i>PA5369.2</i>	2.604799667	0.003142239391	0.03261549984
	<i>PA4280.2</i>	2.596702641	0.003658501903	0.03633497754
	<i>PA0668.4</i>	2.58797494	0.003177734857	0.03286039678
	<i>hcp1</i>	2.353244054	1.14E-22	9.02E-20
	<i>PA0466</i>	1.908730924	1.39E-11	1.30E-09
	<i>pchG</i>	1.899939854	1.07E-08	6.09E-07
	<i>PA0126</i>	1.883859984	5.23E-13	6.57E-11
	<i>PA0050</i>	1.820434031	2.26E-06	7.78E-05
	<i>clpV1</i>	1.75537326	1.53E-11	1.37E-09
	<i>vgrG1</i>	1.730154359	3.27E-12	3.37E-10
	<i>PA4222</i>	1.708263864	2.26E-12	2.45E-10
	<i>PA0563</i>	1.691305244	1.68E-11	1.47E-09
	<i>PA0086</i>	1.677560955	4.89E-10	3.46E-08
Downregulated	<i>PA0627</i>	-2.524464134	1.52E-15	2.79E-13
	<i>gfnR</i>	-2.418533396	8.72E-23	8.02E-20
	<i>PA0641</i>	-2.404904976	2.04E-20	7.49E-18
	<i>PA0638</i>	-2.364308134	4.30E-21	1.98E-18
	<i>PA0628</i>	-2.298437047	1.97E-20	7.49E-18
	<i>PA0635</i>	-2.263949045	1.95E-16	3.84E-14
	<i>PA0629</i>	-2.260720569	5.93E-19	1.92E-16
	<i>PA0639</i>	-2.220599378	2.18E-21	1.21E-18
	<i>PA0636</i>	-2.211742782	4.17E-18	1.15E-15
	<i>PA0625</i>	-2.099597686	3.91E-17	8.30E-15
	<i>PA0616</i>	-2.045775386	2.09E-15	3.72E-13
	<i>PA3638</i>	-2.041401724	2.33E-18	7.14E-16
	<i>PA0634</i>	-1.982462548	1.30E-17	3.00E-15
	<i>PA1168</i>	-1.971155931	1.76E-14	2.56E-12

	PA0631	-1.92975403	4.75E-15	7.95E-13
	PA0619	-1.919212071	1.02E-13	1.31E-11
	PA3631	-1.891142906	4.13E-19	1.43E-16
	PA0626	-1.882097335	5.95E-17	1.22E-14
	PA0630	-1.820934828	4.77E-11	3.71E-09
	PA0637	-1.809932956	1.14E-14	1.75E-12

530

531

532 **Figure 1. Summary of transcriptional responses of *P. aeruginosa* biofilm cells to *C.***

533 ***albicans* and to meropenem treatment.** Numbers of significantly differentially expressed *P.*

534 *aeruginosa* transcripts ($P_{adj} \leq 0.05$) in 1) *P. aeruginosa* single-species biofilms treated with 5

535 $\mu\text{g/mL}$ meropenem; 2) dual species untreated biofilms; 3) dual species biofilms treated with 5

536 $\mu\text{g/mL}$ meropenem; 4) single vs dual species biofilms treated with 5 $\mu\text{g/mL}$ meropenem. PA:

537 *P. aeruginosa*; CA: *C. albicans*. Red: numbers of significantly upregulated transcripts; Blue:

538 numbers of significantly downregulated transcripts.

539

540 **Figure 2. *C. albicans* enhances the tolerance of *P. aeruginosa* to meropenem after short**

541 **exposures.** Preformed 24 hr biofilms were incubated in Mueller Hinton broth containing 0 or

542 5 $\mu\text{g/mL}$ meropenem, for 4 hr and viable *P. aeruginosa* counts quantified. Data are the mean

543 \pm the SEM from 4 biological replicates. Data were analysed using 2-way ANOVA and Holm-

544 Sidak's multiple comparisons test (ns not significant; * $P < 0.05$).

545

546 **Figure 3. Meropenem treatment increases the expression of genes required for biofilm**

547 **formation and iron homeostasis. A) GO term enrichment analysis and B) KEGG analysis**

548 of genes significantly differentially regulated in *P. aeruginosa* single species biofilms by

549 meropenem. Bars in red represent pathways/processes that were significantly upregulated,

550 while bars in blue represent pathways/processes that were significantly downregulated. Data

551 were analysed using Fisher's exact test and Benjamini and Hochberg method for FDR

552 correction (* $FDR \leq 0.05$).

553

554 **Figure 4. *P. aeruginosa* upregulates genes that provide a competitive fitness advantage**

555 **during growth in dual species biofilms. A) GO term enrichment analysis and B) KEGG**

556 analysis of *P. aeruginosa* genes significantly differentially regulated in dual species biofilms.

557 Bars in red represent pathways/processes that were significantly upregulated, while bars in

558 blue represent pathways/processes that were significantly downregulated. Data were

559 analysed using Fisher's exact test and Benjamini and Hochberg method for FDR correction (*
560 $FDR \leq 0.05$).

561

562 **Figure 5. Dual species biofilms do not perturb the *P. aeruginosa* transcriptional**
563 **response to meropenem. A)** GO term enrichment analysis and **B)** KEGG analysis of *P.*
564 *aeruginosa* genes significantly differentially regulated in dual species biofilms in response to
565 meropenem treatment. Bars in red represent pathways/processes that were significantly
566 upregulated, while bars in blue represent pathways/processes that were significantly
567 downregulated. Data were analysed using Fisher's exact test and Benjamini and Hochberg
568 method for FDR correction (* $FDR \leq 0.05$).

569

570 **Figure 6. Identification of overlapping differentially expressed genes in *P. aeruginosa***
571 **mono and dual species biofilms in response to meropenem.** Numbers of significantly
572 upregulated (a) and downregulated (b) genes ($P_{adj} \leq 0.05$), in response to treatment with 5
573 $\mu\text{g/mL}$ meropenem, are compared between single- and dual-species biofilms (PA *P.*
574 *aeruginosa*; CA *C. albicans*). Genes of interest, unique to the dual-species condition, are listed
575 on the right-hand side.

576

577 **Supplemental Figure 1. PCA plots A)** single species *P. aeruginosa* in response to
578 meropenem. **B)** Dual species biofilms in the absence of meropenem. **C)** Dual species biofilms
579 in the presence of meropenem.

580

581 **Supplemental Figure 2. Transcriptional profiling identifies genes differential regulated**
582 **in single and dual species biofilms in response to meropenem.** Volcano plots identifying
583 significantly differentially regulated genes in **A)** single species *P. aeruginosa* in response to
584 meropenem. **B)** Dual species biofilms in the absence of meropenem. **C)** Dual species biofilms
585 in the presence of meropenem.

586

587